Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 75

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 75
---
 of transaction expenses (excluding the deferred underwriting commissions being held in the Trust Account). Accordingly, FutureTech may not be able to reimburse these expenses if the Business Combination or another business combination, is not completed by such date.

Pursuant to the A&R Registration Rights Agreement, the Sponsor, certain stockholders of Longevity, and certain stockholders of FutureTech will have the right to require FutureTech, at FutureTech’s expense, to register FutureTech common stock that they hold on customary terms for a transaction of this type, including customary demand and piggyback registration rights. The A&R Registration Rights Agreement will also provide that FutureTech will pay certain expenses of the electing holders relating to such registrations and indemnify them against certain liabilities that may arise under the Securities Act.

The existence of financial and personal interests of one or more of FutureTech’s directors may result in a conflict of interest on the part of such director(s) between what he, she or they may believe is in the best interests of FutureTech and its stockholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that stockholders vote for the proposals. In addition, FutureTech’s officers have interests in the Business Combination that may conflict with your interests as a stockholder. See the section entitled “ Proposal No. 1 — The Business Combination Proposal — Interests of FutureTech’s Directors and Executive Officers in the Business Combination” for a further discussion of these considerations.

The personal and financial interests of the Sponsor as well as the FutureTech Board and officers may have influenced their motivation in identifying and selecting Longevity as a business combination target, completing an initial business combination with Longevity and influencing the operation of the business following the Business Combination. In considering the recommendations of the FutureTech Board to vote for the proposals, its stockholders should consider these interests.

| 24 |

The exercise of FutureTech’s directors’ and executive officers’ discretion in agreeing to changes or waivers in the terms of the Business Combination may result in a conflict of interest when determining whether such changes to the terms of the Business Combination or waivers of conditions are appropriate and in FutureTech’s stockholders’ best interest.

In the period leading up to the Closing, events may occur that, pursuant to the Merger Agreement, would require FutureTech to agree to amend the Merger Agreement, to consent to certain actions taken by Longevity or to waive rights to which FutureTech is entitled to under the Merger Agreement. Such events could arise because of changes in